More than 60 genetic diseases are currently known to directly or indirectly affect kidney function. These diseases range from relatively common to very rare and can impact kidney functions in infants to adults. Many of these diseases are progressive and eventually lead to chronic kidney disease (CKD) and eventually end stage renal disease (ESRD). Unfortunately, for the majority there are no disease modifying therapeutic options and patients eventually resort to renal replacement therapies (RRT) including chronic dialysis or transplant. With their high prevalence and limited therapeutic options, these kidney diseases present a significant health care and economic challenge.
While our initial focus is on developing therapies for genetic diseases associate with GSL metabolism, AceLink’s goal is to diversify the pipeline by developing therapies that address the unmet clinical need for a broader set of kidney diseases such as diabetic nephropathy, IgA nephropathy, or kidney stone related kidney damage.